For the year ending 2025-12-31, AURX had $265,232 increase in cash & cash equivalents over the period. -$1,139,727 in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -2,512,216 |
| Depreciation expense | 85,463 |
| Stock-based compensation | 85,986 |
| Provision for credit losses | 91,401 |
| Provision for inventory obsolescence | 19,371 |
| Vendor expense settled in shares of common stock | 51,000 |
| Gain on settlement of accounts payable | 0 |
| Amortization of operating lease right of use assets | 71,476 |
| Accounts receivable, net | 404,863 |
| Inventory, net | 82,690 |
| Prepaid expenses and other current assets | -103,676 |
| Accounts payable | 216,893 |
| Accrued expenses | 201,392 |
| Deferred revenue | 1,275,000 |
| Operating lease liabilities | -66,860 |
| Net cash used in operating activities | -864,971 |
| Purchases of property and equipment | 274,756 |
| Net cash used in investing activities | -274,756 |
| Net proceeds from issuance of common stock | 791,418 |
| Net proceeds from option exercises | 113,541 |
| Net proceeds from note payable issuance related party-Nonrelated Party | 300,000 |
| Net proceeds from note payable issuance related party-Related Party | 200,000 |
| Net proceeds from warrant exercise | 0 |
| Net cash provided by financing activities | 1,404,959 |
| Net decrease in cash | 265,232 |
| Cash, beginning of period | 283,714 |
| Cash, end of period | 548,946 |
Nuo Therapeutics, Inc. (AURX)
Nuo Therapeutics, Inc. (AURX)